Using Patient-Reported Quality of Life Measures to Evaluate Catheter Ablation and Drug Therapy for Ventricular Tachycardia in Adults with ICDs

What this Trial Is About

Researchers are evaluating whether more frequent collection of patient reported outcome measures, especially health related quality of life HRQL, can improve how well the clinical and cost effectiveness of catheter ablation for ventricular tachycardia VT is understood. This study focuses on patients with an Implantable Cardioverter Defibrillator ICD who are at risk of dangerous heart rhythm problems. It aims to assess the feasibility of this monitoring approach to better capture changes in patients quality of life and clinical status. The study compares two groups patients undergoing catheter ablation of VT and those receiving anti-arrhythmic drug AAD therapy. Participants will complete validated quality of life questionnaires EQ-5D and C-CAP at baseline and at multiple time points over one year. The study takes place at a single center where patients are identified through outpatient VT clinics. This approach allows monitoring of quality of life changes more frequently than in previous trials. Participants will be followed for one year with repeated HRQL assessments at 1, 2, 3, 4, 6, 9, and 12 months. Researchers will track completion rates of these forms, recruitment rates, patient preferences for paper or electronic questionnaires, and HRQL outcomes. They will also evaluate the impact of this data on cost-effectiveness calculations for VT ablation. The study focuses on feasibility and improving the understanding of patient experiences with these treatments.

Improving Patient Reported Outcome Measures in Catheter Ablation